How to manage immune-related adverse effects in lung cancer patients under immunotherapy Source: CME Online 2019 Year: 2018
Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021
Re-challenge of immunotherapy in a lung cancer patient Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021
Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007
Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020
Boosting immunotherapy in lung cancer Source: International Congress 2017 – ME9 Boosting immunotherapy in lung cancer Year: 2017
Do cavitating non-small cell lung cancer patients have a more aggressive disease? Source: Eur Respir J 2006; 28: Suppl. 50, 84s Year: 2006
Impact of antibiotics on immunotherapy response in lung cancer patients Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019
Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011
Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004
Non-small cell lung cancer - oral navelbine single-agent chemotherapy in elderly patient advanced stage or metastatic disease Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004
Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009